Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Care Reform's 340B Provisions Could Impact Oncology Near-Term

Executive Summary

Companies with oncology products should take a look at the health reform law's provisions on the 340B drug discount program when assessing the new law's early impact, a review by the consulting firm KantarHealth suggests
Advertisement

Related Content

Higher Medicaid Rebates Expected To Boost Private Payer Discounts Too
Higher Medicaid Rebates Expected To Boost Private Payer Discounts Too
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
Final Health Reform Bill Looks Positive For Pharma Firms

Topics

Advertisement
UsernamePublicRestriction

Register

PS052113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel